• FDA approves Plus Therapeutics’ Reyobiq for paediatric brain cancer
    June 26, 2025 from PBR - News
    Paediatric HGG, including ependymoma, are not only rare but also very difficult to treat, with current standard care failing to prevent recurrence and with five-year survival rates. Reyobiq The post FDA approves Plus Therapeutics’...
  • EC grants orphan drug status to JR-446 for MPS IIIB
    June 26, 2025 from PBR - News
    This follows a similar endorsement by the US Food and Drug Administration (FDA). Sanfilippo syndrome type B is an autosomal recessive disease marked by mutations in the N-acetyl-alpha-glucosaminidase The post EC grants orphan drug status...
  • Optime Care collaborates with Tilde Sciences for Vecamyl tablets
    June 24, 2025 from PBR - News
    This collaboration appoints Optime Care as the exclusive specialty pharmacy provider for the newly FDA-approved tablets, ensuring the medication’s availability to patients.  Optime Care general manager Bill Bertetto The post Optime...
  • Archeus Technologies gets FDA approval for ART-101 application
    June 24, 2025 from PBR - News
    This new small molecule is designed for prostate cancer imaging and treatment.   The FDA’s approval allows Archeus to begin a Phase I clinical study targeting metastatic castration-resistant prostate The post Archeus Technologies...
  • CHMP endorses ExCellThera’s stem cell transplantation product
    June 20, 2025 from PBR - News
    The therapy is intended to treat the adult population with haematological malignancies needing an allogeneic haematopoietic stem cell transplantation after a myeloablative conditioning for those individuals with no The post CHMP endorses...
  • Johnson & Johnson submits sBLA to FDA to extend use of ustekinumab
    June 20, 2025 from PBR - News
    The application is underpinned by the multi-centre, open-label Phase III UNITI-Jr clinical trial data, which assessed the therapy’s safety, pharmacokinetics, and efficacy in paediatric subjects. At present, Stelara The post Johnson...
  • Ferrer’s progressive supranuclear palsy therapy gains FDA fast track status
    June 20, 2025 from PBR - News
    In-licensed from Asceneuron, this new molecular entity is currently undergoing a Phase II trial. The trial aims to assess the therapy’s efficacy, pharmacokinetics, and safety in adults diagnosed The post Ferrer’s progressive...
  • FDA grants fast-track status to SolasCure’s gel for calciphylaxis ulcers
    June 20, 2025 from PBR - News
    This status signifies the potential of the gel to broaden its therapeutic applications in chronic wound healing, accelerating its availability to patients. SolasCure noted that this hydrogel releases The post FDA grants fast-track status...
  • MRI and Astellas to support Japanese drug-discovery startups
    June 20, 2025 from PBR - News
    This collaboration is expected to strengthen the country’s role as an international hub for drug discovery. This new support is part of several programmes under the Medical Innovation The post MRI and Astellas to support Japanese...
  • Health Canada authorises Roche’s PiaSky for PNH
    June 20, 2025 from PBR - News
    PiaSky will be given as the first monthly subcutaneous therapy for adults and adolescents aged 13 years or more with a minimum body weight of 40kg. Patients have The post Health Canada authorises Roche’s PiaSky for PNH appeared first on...
  • AI could accelerate protein engineering - key for developing new medicines
    June 20, 2025 from Breaking World Pharma News
    In a study published in the journal Nature Machine Intelligence, Sheffield computer scientists in collaboration with AstraZeneca and the University of Southampton have developed a new machine learning framework that has shown the...
  • AstraZeneca enters strategic collaboration with CSPC Pharmaceuticals focused on AI-enabled research
    June 19, 2025 from Breaking World Pharma News
    AstraZeneca has entered a strategic research collaboration with Shijiazhuang City-based CSPC Pharmaceuticals Group Limited. Working together on high priority targets, the collaboration aims to advance the discovery and development of...
  • Researchers identify a protein that may help improve the treatment of obesity and cardiovascular disease
    June 18, 2025 from Breaking World Pharma News
    Obesity, diabetes and cardiovascular diseases are increasingly present in the population. Brown adipose tissue has a protective function against these prevalent diseases, as it burns calories and can produce body heat from fat. But as...
  • New strategy for the treatment of severe childhood cancer
    June 17, 2025 from Breaking World Pharma News
    Researchers at Karolinska Institutet and Lund University in Sweden have identified a new treatment strategy for neuroblastoma, an aggressive form of childhood cancer. By combining two antioxidant enzyme inhibitors, they have converted...
  • Groundbreaking TACIT algorithm offers new promise in diagnosing, treating cancer
    June 16, 2025 from Breaking World Pharma News
    Researchers at VCU Massey Comprehensive Cancer Center have developed a novel algorithm that could provide a revolutionary tool for determining the best options for patients - both in the treatment of cancer and in the prescription of...
  • Smartphone tests could accelerate drug development for Huntington's disease
    June 13, 2025 from Breaking World Pharma News
    A series of digital tests, carried out via a smartphone app, could enhance the detection of disease progression in Huntington's disease and improve the efficiency of clinical trials, finds research led by scientists at University College...
  • Vividion Therapeutics and Bayer further strengthen oncology development pipeline with clinical-stage WRN inhibitor
    June 12, 2025 from Breaking World Pharma News
    Vividion Therapeutics, Inc. (Vividion), a clinical-stage biopharmaceutical company, and a wholly owned and independently operated subsidiary of Bayer AG, announced it has secured exclusive worldwide rights to develop and commercialize...
  • Ultra-selective aptamers give viruses a taste of their own medicine
    June 11, 2025 from Breaking World Pharma News
    We have all heard of antibodies - proteins produced by our bodies to bind to viruses or bacteria, marking them for elimination by the immune system. But not all of us are familiar with aptamers: short segments of DNA or RNA that are...
  • Fermenting legume pulses boosts their antidiabetic, antioxidant properties
    June 10, 2025 from Breaking World Pharma News
    Food scientists at the University of Illinois Urbana-Champaign identified the optimal fermentation conditions for pulses - the dried edible seeds of legumes - that increased their antioxidant and antidiabetic properties and their soluble...
  • Improving T cell responses to vaccines
    June 9, 2025 from Breaking World Pharma News
    In the quest to design vaccines that better help the body's immune system fight disease, scientists are always looking for more tools for their arsenal. The strong antibody responses generated by vaccines provide an important first round...
  • ISTH: new data highlight innovation from Sanofi's pipeline in rare diseases
    June 6, 2025 from Breaking World Pharma News
    New data from 18 abstracts, including five oral presentations, will be presented at the 33rd congress of the International Society on Thrombosis and Haemostasis (ISTH) in Washington D.C., US from June 21 to 25, 2025, highlighting Sanofi...
  • Fighting myeloma with fiber: Plant-based diet offers promise
    June 5, 2025 from Breaking World Pharma News
    Results from a new clinical trial suggest that a high-fiber plant-based diet could benefit patients at risk for developing multiple myeloma, the second most common type of blood cancer. The study showed that the diet was not only...
  • Collaborations result in antibiotic resistance breakthrough
    June 4, 2025 from Breaking World Pharma News
    University of Otago - Ōtākou Whakaihu Waka researchers have been part of two groundbreaking studies in the battle against drug resistant strains of Mycobacterium tuberculosis, the cause of tuberculosis. Co-author on both studies, Dr...
  • Tea, berries, dark chocolate and apples could lead to a longer life span
    June 3, 2025 from Breaking World Pharma News
    New research has found that those who consume a diverse range of foods rich in flavonoids, such as tea, berries, dark chocolate, and apples, could lower their risk of developing serious health conditions and have the potential to live...
  • Application of machine learning in drug side effect prediction: databases, methods and challenges
    June 2, 2025 from Breaking World Pharma News
    Understanding and preventing drug side effects holds a profound influence on drug development and utilization, profoundly impacting patients' physical and mental well-being. Traditional artificial drug experimentation methods are not...
  • DeepSeek-R1 offers promising potential to accelerate healthcare transformation
    May 30, 2025 from Breaking World Pharma News
    A joint research team from The Hong Kong University of Science and Technology and The Hong Kong University of Science and Technology (Guangzhou) has published a perspective article in MedComm - Future Medicine. The article...
  • Sevabertinib (BAY 2927088) granted FDA Priority Review for the treatment of patients with HER2-mutant non-small cell lung cancer
    May 29, 2025 from Breaking World Pharma News
    Bayer announced that the investigational compound sevabertinib (BAY 2927088) has been granted Priority Review status by the US Food and Drug Administration (FDA) for the treatment of adult patients with advanced non-small cell lung...
  • Researchers identify drug candidate for difficult-to-treat heart disease
    May 28, 2025 from Breaking World Pharma News
    A study led by a physician-scientist at the University of Arizona College of Medicine - Tucson's Sarver Heart Center identified a drug candidate that appears to reverse the progression of a type of heart failure in mouse models, which...
  • Potential new treatment for Alzheimer's disease, other neurodegenerative conditions
    May 27, 2025 from Breaking World Pharma News
    Worldwide, more than 55 million people suffer from dementia caused by Alzheimer's Disease (AD) and other conditions that destroy cells in the brain and nervous system. While there is no treatment to control or manage these...
  • Common antidepressants could help the immune system fight cancer
    May 26, 2025 from Breaking World Pharma News
    A widely used antidepressant drug could help the immune system fight cancer, according to a new UCLA research study. Selective serotonin reuptake inhibitors, or SSRIs, significantly enhanced the ability of T cells to fight cancer and...
  • Takeda’s Eohilia approved by FDA as first oral therapy for eosinophilic oesophagitis
    February 16, 2024 from PMLiVE RSS Feed: News RSS
    The inflammatory disease affects around one in 2,000 people in the US
  • Sanofi's investigational frexalimab shows promise in relapsing forms of MS
    February 16, 2024 from PMLiVE RSS Feed: News RSS
    Results from a mid-stage of the candidate were recently published in the NEJM
  • UCB presents positive phase 3 results for bimekizumab in hidradenitis suppurativa
    February 16, 2024 from PMLiVE RSS Feed: News RSS
    The skin disease affects an estimated 1% of the population in most studied countries
  • PrecisionLife and Metrodora Institute partner for diagnosis and treatment of chronic diseases
    February 16, 2024 from PMLiVE RSS Feed: News RSS
    The collaboration will first focus on developing products for long COVID and ME/CFS
  • ICR scientists identify new way to study important driver of breast cancer
    February 16, 2024 from PMLiVE RSS Feed: News RSS
    Researchers used a technique to identify specific molecular details of biotin-labelled proteins
  • Ipsen’s Onivyde regimen granted FDA approval to treat pancreatic cancer
    February 15, 2024 from PMLiVE RSS Feed: News RSS
    Around 60,000 people are diagnosed with pancreatic adenocarcinoma in the US every year
  • Biogen receives EC approval for Skyclarys in Friedreich’s ataxia patients
    February 15, 2024 from PMLiVE RSS Feed: News RSS
    The company gained access to the drug through its $7.3bn acquisition of Reata Pharmaceuticals
  • New type of inhibitor drug could prevent microvascular diabetic complications
    February 15, 2024 from PMLiVE RSS Feed: News RSS
    The drug could prevent conditions including diabetic eye and kidney disease in diabetes
  • MHRA launches second phase of genetic biobank for stroke prevention medicines
    February 15, 2024 from PMLiVE RSS Feed: News RSS
    The Yellow Card Biobank will begin investigating direct oral anticoagulants such as apixaban
  • Gilead expands liver disease pipeline with $4.3bn CymaBay acquisition
    February 14, 2024 from PMLiVE RSS Feed: News RSS
    The deal gives the company access to a candidate being evaluated in primary biliary cholangitis
  • EC approves Vertex/CRISPR’s Casgevy gene therapy for inherited blood disorders
    February 14, 2024 from PMLiVE RSS Feed: News RSS
    There are now more than 8,000 patients who are potentially eligible for treatment with Casgevy
  • BioMarin shares long-term results for haemophilia A gene therapy Roctavian
    February 14, 2024 from PMLiVE RSS Feed: News RSS
    Approximately one in 10,000 people are affected by the genetic blood clotting disorder
  • Sanofi presents positive results for Pompe disease enzyme replacement therapy
    February 14, 2024 from PMLiVE RSS Feed: News RSS
    The rare genetic disorder is estimated to affect around one in every 40,000 people in the UK
  • ICR researchers reveal how advanced breast cancers become resistant to hormone therapy
    February 14, 2024 from PMLiVE RSS Feed: News RSS
    F404 mutations combined with pre-existing mutations caused resistance to fulvestrant
  • BioNTech and Autolus enter CAR-T cell therapy collaboration worth over $250m
    February 13, 2024 from PMLiVE RSS Feed: News RSS
    Both companies will leverage their autologous CAR-T cell therapy programmes
  • Ten23 health expands former swissfillon facility in Visp, Switzerland
    March 28, 2022 from FiercePharmaManufacturing News
    Ten23 health expands former swissfillon facility in Visp, Switzerland jkeenan Mon, 03/28/2022 - 08:41
  • Sobi to trim staff as Pfizer manufacturing contract ends early
    March 24, 2022 from FiercePharmaManufacturing News
    Sobi to trim staff as Pfizer manufacturing contract ends early jkeenan Thu, 03/24/2022 - 08:40
  • Epinephrine recall: Adamis pulls Symjepi injections for needle clogging risks
    March 23, 2022 from FiercePharmaManufacturing News
    Epinephrine recall: Adamis pulls Symjepi injections for needle clogging risks aliu Wed, 03/23/2022 - 11:18
  • Fujifilm makes yet another deal to jack up cell and gene therapy capacity
    March 22, 2022 from FiercePharmaManufacturing News
    Fujifilm makes yet another deal to jack up cell and gene therapy capacity kdunleavy Tue, 03/22/2022 - 21:13
  • Takeda's Natpara relaunch bid falls flat as manufacturing concerns drag on
    March 22, 2022 from FiercePharmaManufacturing News
    Takeda's Natpara relaunch bid falls flat as manufacturing concerns drag on jkeenan Tue, 03/22/2022 - 09:22
  • Powered by Feed Informer